Imunon, Inc. (IMNN)

Imunon Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	0.5	0.5	0.5
Cost of Revenue	-	-	-	10.62	11.34
Gross Profit	-	-	0.5	-10.12	-10.84
Selling, General & Admin	7.49	9.74	13.69	10.89	7.64
Research & Development	11.64	11.29	11.73	-	-
Operating Expenses	19.13	21.03	25.42	10.89	7.64
Operating Income	-19.13	-21.03	-24.92	-21.01	-18.49
Interest Expense	-	-0.2	-5.03	-0.57	-1.29
Interest & Investment Income	0.51	1.16	0.45	0.01	0.12
Other Non Operating Income (Expenses)	-	-0.4	0	0	0
EBT Excluding Unusual Items	-18.62	-20.47	-29.5	-21.56	-19.66
Impairment of Goodwill	-	-	-	-1.98	-
Other Unusual Items	-	-0.33	5.4	1.39	-1.3
Pretax Income	-18.62	-20.8	-37.47	-22.15	-23.33
Income Tax Expense	-	-1.28	-1.57	-1.38	-1.85
Net Income	-18.62	-19.51	-35.9	-20.77	-21.48
Net Income to Common	-18.62	-19.51	-35.9	-20.77	-21.48
Shares Outstanding (Basic)	12	9	7	5	2
Shares Outstanding (Diluted)	12	9	7	5	2
Shares Change (YoY)	27.23%	26.63%	31.62%	154.70%	46.39%
EPS (Basic)	-1.62	-2.16	-5.03	-3.83	-10.08
EPS (Diluted)	-1.62	-2.16	-5.03	-3.83	-10.08
Free Cash Flow	-18.88	-19.47	-23.36	-16.54	-15.64
Free Cash Flow Per Share	-1.64	-2.15	-3.27	-3.05	-7.34
Gross Margin	-	-	100.00%	-	-
Operating Margin	-	-	-4984.31%	-4201.44%	-3697.28%
Profit Margin	-	-	-7179.65%	-4153.85%	-4296.71%
Free Cash Flow Margin	-	-	-4672.94%	-3307.04%	-3127.55%
EBITDA	-18.89	-20.78	-24.73	-20.3	-17.74
D&A For EBITDA	0.24	0.25	0.2	0.7	0.74
EBIT	-19.13	-21.03	-24.92	-21.01	-18.49

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q